Edition:
United Kingdom

Emami Ltd (EMAM.NS)

EMAM.NS on National Stock Exchange of India

1,072.20INR
23 Feb 2018
Change (% chg)

Rs12.45 (+1.17%)
Prev Close
Rs1,059.75
Open
Rs1,063.85
Day's High
Rs1,080.00
Day's Low
Rs1,061.00
Volume
34,912
Avg. Vol
171,572
52-wk High
Rs1,365.00
52-wk Low
Rs990.00

Latest Key Developments (Source: Significant Developments)

India's Emami Dec-Qtr Consol Profit Rises
Monday, 29 Jan 2018 

Jan 29 (Reuters) - Emami Ltd ::DEC QUARTER CONSOL NET PROFIT 1.47 BILLION RUPEES VERSUS PROFIT 1.34 BILLION RUPEES YEAR AGO.DEC QUARTER CONSOL REVENUE FROM OPERATIONS 7.57 BILLION RUPEES VERSUS 7.26 BILLION RUPEES YEAR AGO.  Full Article

India's Emami Acquires 30 Pct Stake In Helios Lifestyle
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Emami Ltd ::EMAMI LTD - AGREED TO INVEST IN HELIOS LIFESTYLE BY SUBSCRIBING TO SHARES EQUIVALENT TO 30 PERCENT OF ISSUED SHARE CAPITAL IN 2 TRANCHES BY DEC 31, 2018.  Full Article

India's Emami Sept-qtr consol profit up 49 pct
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Emami Ltd ::Sept quarter consol profit after tax 986 million rupees versus profit of 658.7 million rupees last year.Sept quarter consol revenue from operations 6.28 billion rupees versus 5.84 billion rupees last year.Consensus forecast for Sept quarter consol profit was 1.01 billion rupees.  Full Article

Emami Ltd June-qtr consol profit down about 35 pct
Wednesday, 3 Aug 2016 

Emami Ltd : June-quarter consol net profit 566.5 million rupees; June-quarter consol net sales 6.43 billion rupees . Consol net profit in June quarter last year was 866.1 million rupees as per Ind-AS; consol net sales was 5.37 billion rupees .  Full Article

Emami Ltd's board recommends dividend
Thursday, 5 May 2016 

Emami Ltd:Recommends dividend of 700% ( 7 Indian rupees per equity share of 1 Indian rupees-) for the financial year ended March 31, 2016.  Full Article

BRIEF-India's Emami To Make Strategic Investment In Brillare Science

* TO MAKE STRATEGIC INVESTMENT IN BRILLARE SCIENCE PVT LTD Source text - http://bit.ly/2EghQuF Further company coverage:

No consensus analysis data available.